Navigation Links
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
Date:5/23/2011

PARSIPPANY, N.J., May 23, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that clinical data highlighting the safety profile of EXPAREL™ (bupivacaine extended-release liposome injection) will be presented at the 2011 International Anesthesia Research Society (IARS) Annual Meeting in Vancouver, British Columbia.

Comprehensive, program-wide safety data for EXPAREL will be presented by Dr. Eugene R. Viscusi, Director, Acute Pain Management, Department of Anesthesiology, Jefferson Medical College, Thomas Jefferson University, on Monday, May 23, 2011 at 2:45 p.m. ET. Dr. Viscusi's presentation, titled "The Safety of EXPAREL™, A Multivesicular Liposomal Extended-Release Bupivacaine" examines the safety profile of EXPAREL in 823 patients across ten wound infiltration studies and five surgical procedures, including hemorrhoidectomy, bunionectomy, total knee arthroplasty, breast augmentation and hernia repair.

Pacira also announced that comprehensive, program-wide efficacy data for EXPAREL was highlighted at IARS. Dr. Sergio Bergese, associate professor of anesthesiology and neurological surgery, The Ohio State University, presented the poster, titled, "The Efficacy of EXPAREL™, A Multivesicular Liposomal Extended-Release Bupivacaine" on Sunday, May 22, 2011 at 8 a.m. ET. The poster was previously presented May 11, 2011 at the Society for Ambulatory Anesthesia (SAMBA) 26th Annual Meeting in San Antonio; this is the first time that the program wide efficacy and safety data have been presented together.

"We are excited to present these data, which support the utility of EXPAREL across multiple surgical models," said David Stack, president and chief executive officer of Pacira Pharmaceuticals. "While EXPAREL was well-tolerated across all doses, based upon clinical experience
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Cynosure, Inc. (Nasdaq: ... and light-based aesthetic treatment systems for high-volume applications, today ... 30, 2014. Second-quarter 2014 financial results incorporate the acquisition ... 24, 2013. Second-Quarter 2014 Financial ... to $72.6 million , Non-GAAP net income of ...
(Date:7/29/2014)...  The Healthcare Analytics Summit 2014 (HAS ... Salt Lake City , Sept. 24-25 has added ... organizations in the U.S. and beyond.  HAS ,14, powered ... devoted to providing immersive learning experiences on the ... accountable care initiatives and population health managemen t ...
(Date:7/29/2014)... , July 29, 2014 Apex Medical Corporation ... and Pressure Area Care sectors, announces that it is appealing ... in Germany that found ... Apex notes that it has initiated invalidity challenges against various ... efforts in counterattacking against trivial and junk patents. ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Apex Continues Fighting Against Patents to Free Up Competition 2
... initiate Phase 1 trial of AKIi-5 as the first ... ... Aug. 2 Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company ... today the,presentation of positive results from preclinical efficacy studies ...
... PHILADELPHIA, Aug. 3 GlaxoSmithKline (NYSE:,GSK), one of ... has placed another order to purchase bulk H5N1 ... The company also announced the,start of the first ... pre-pandemic influenza program. HHS Order The ...
Cached Medicine Technology:Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 2Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 3Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 4GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 2GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 3GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 4
(Date:7/29/2014)... Roanoke, Virginia (PRWEB) July 29, 2014 ... a featured lecturer at the Florida Chiropractic Association (FCA) ... and Their Effects on the Kinetic Chain Changes on ... Florida. Greenawalt’s talk is focusing on the positive impact ... on conditions such as low back pain, plantar fasciitis, ...
(Date:7/29/2014)... 29, 2014 Healthcare staffing agency ... Nurses of Tomorrow Scholarship Competition winners:, ... NV ,     Racheal D., Freshman, Cerritos College ... Houston Community College in Houston, TX ... Medical Solutions hosts the Nurses of Tomorrow Scholarship ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 PharmaSphere: ... Biosimilars Market report is an essential source of ... Using detailed company data, financial analysis, corporate strategy, ... of the current and future growth drivers of ... regulatory frameworks under which biosimilars are currently reviewed ...
(Date:7/29/2014)... 29, 2014 1WorldSync announces B. ... healthcare suppliers will utilize the Global Data Synchronization ... network to share product information with the U.S. ... partners across their global supply chain. Holger Clobes, ... B. Braun: "B. Braun serves customers in 61 ...
(Date:7/29/2014)... Catalent Pharma Solutions, the global leader ... for pharmaceutical, biologic, and consumer health products, today ... US Platform Leader of Pharmaceutical Softgels, will present ... Formulations using Soft Capsule Delivery Systems” at the ... of Drug Delivery Systems (30-31 July 2014, Tokyo, ...
Breaking Medicine News(10 mins):Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2
... pre-packed Camembert to shrink-wrapped meat loaf choosing the ... industry. Companies need to protect food products from oxygen, ... fresh for as long as possible. Transparent multilayer films, ... used to protect food from contamination. To minimize the ...
... Tuning in to tune out may be just what,s ... at the Duke Cancer Institute. The Duke team found ... pain and anxiety of the often uncomfortable procedure. The ... points to a simple and inexpensive way to help an ...
... This release is available in Spanish . ... gather and characterise in detail 110 cases of cardiac rupture ... Hospital de Cruces, near Bilbao. It is one of the ... most serious complication of acute myocardial infarction; it is not ...
... new study by NYU Langone Medical Center researchers identified ... of fat and cholesterol that hardens into plaque and ... Immunology on January 8, 2012, explains why cholesterol-laden, ... plaques. "We have discovered that macrophages that accumulate ...
... , SUNDAY, Jan. 8 (HealthDay News) -- People ... genes as those in the general population, but they may ... so long, researchers report. The team of U.S. scientists ... with only one per 5 million people in developed nations. ...
... at the Translational Genomics Research Institute (TGen) have begun ... to lung cancer in never-smokers a first step ... starting point. We certainly have a lot of pathways ... very interested in confirming and looking at in larger ...
Cached Medicine News:Health News:Film coatings made from whey 2Health News:Film coatings made from whey 3Health News:Headphone music eases anxiety during prostate biopsies 2Health News:Keys for detecting cardiac rupture 2Health News:Keys for detecting cardiac rupture 3Health News:Researchers discover new culprit in atherosclerosis 2Health News:Why Some People Live to 110 2Health News:TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers 2
... is an excellent choice to treat DeQuervain's ... joint, basal joint arthritis, advanced carpal tunnel ... thumb and wrist. Distal palmar crease ... and full finger dexterity. Constructed from ...
... Wrist Flex is a custom wrist orthotic designed to ... to the patient's maximum range-of-motion. , ,Indications: , ... TFCC tear-triangular fibrocartilage complex , Coles fracture ... , Partial tendon rupture , ORIF ...
The Contoured Wrist/Forearm Support provides comfort for post-surgical immobilization, post-fracture casting, and wrist sprains and strains....
Design allows for easy-one hand application to provide support and immobilization of the wrist while preserving finger mobility...
Medicine Products: